BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia
Authors:
- Niuscha YaktapourNYNiuscha Yaktapour
- Frank MeissFMFrank Meiss
- Justin MastroianniJMJustin Mastroianni
- Thorsten ZenzTZThorsten Zenz
- Hana AndrlovaHAHana Andrlova
- Nimitha R. MathewNMNimitha R. Mathew
- Rainer ClausRCRainer Claus
- Barbara HutterBHBarbara Hutter
- Stefan FröhlingSFStefan Fröhling
- Benedikt BrorsBBBenedikt Brors
- Dietmar PfeiferDPDietmar Pfeifer
- Milena PanticMPMilena Pantic
Open Access
- 20 October 2014
- journal article
- case report
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 124 (11) , 5074-5084
Abstract
Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway. In BRAF WT cells and those with mutations that activate or result in high levels of the BRAF activator RAS, BRAF inhibition can lead to ERK activation, resulting in tumorigenic transformation. We describe a patient with malignant melanoma who developed chronic lymphocytic leukemia (CLL) in the absence of RAS mutations during vemurafenib treatment. BRAF inhibition promoted patient CLL proliferation in culture and in murine xenografts and activated MEK/ERK in primary CLL cells from additional patients. BRAF inhibitor–driven ERK activity and CLL proliferation required B cell antigen receptor (BCR) activation, as inhibition of the BCR-proximal spleen tyrosine kinase (SYK) reversed ERK hyperactivation and proliferation of CLL cells from multiple patients, while inhibition of the BCR-distal Bruton tyrosine kinase had no effect. Additionally, the RAS-GTP/RAS ratio in primary CLL cells exposed to vemurafenib was reduced upon SYK inhibition. BRAF inhibition increased mortality and CLL expansion in mice harboring CLL xenografts; however, SYK or MEK inhibition prevented CLL proliferation and increased animal survival. Together, these results suggest that BRAF inhibitors promote B cell malignancies in the absence of obvious mutations in RAS or other receptor tyrosine kinases and provide a rationale for combined BRAF/MEK or BRAF/SYK inhibition.Keywords
This publication has 49 references indexed in Scilit:
- Progression of RAS-Mutant Leukemia during RAF Inhibitor TreatmentNew England Journal of Medicine, 2012
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Dissecting the genomic complexity underlying medulloblastomaNature, 2012
- Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signallingThe EMBO Journal, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Integrative genomics viewerNature Biotechnology, 2011
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010